Achieve Life Sciences (ACHV) Non-Current Deffered Revenue (2010 - 2011)
Achieve Life Sciences (ACHV) posted Non-Current Deffered Revenue of $9.0 million for Q3 2011, down 8.41% on a QoQ basis from $9.9 million in Q2 2011.
Achieve Life Sciences (ACHV) Non-Current Deffered Revenue (2010 - 2011) Analysis & Trends
Achieve Life Sciences' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $9.0 million for Q3 2011.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $9.0 million in Q3 2011, while the trailing twelve-month figure through Sep 2011 was $9.0 million (changed N/A YoY) and the FY2010 annual result came in at $11.6 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $9.0 million for Q3 2011 at Achieve Life Sciences, down from $9.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $11.6 million in Q4 2010 and bottomed at $9.0 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Achieve Life Sciences | 2.54 Mn | 2.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 9.04 Mn |
| Jun 30, 2011 | 9.87 Mn |
| Dec 31, 2010 | 11.62 Mn |